30.09.2011 • NewsViroPharmaDrug Developmentorphan drug

ViroPharma Licenses Rights from Intellect Neurosciences for Friedreich's Ataxia

ViroPharma announced the license of worldwide rights from Intellect Neurosciences to its clinical stage drug candidate, OX1, being developed for the treatment of Friedreich's Ataxia, a rare, hereditary, progressive neurodegenerative disease.

OX1, or indole-3-propionic acid or IPA, is a naturally occurring, small molecule that has potent anti-oxidant properties that can protect against neurodegenerative disease.

In a recent Phase 1 safety and tolerability study conducted in the Netherlands, OX1 was demonstrated to be safe and well tolerated at all dose levels tested. ViroPharma expects to initiate a phase 2 study within 12 to 18 months after completion of longer term toxicology studies. ViroPharma intends to file for Orphan Drug Designation upon review of the phase 2 proof of concept data.

As per the deal terms, ViroPharma has exclusive worldwide rights to develop and commercialize OX1 for the treatment, management or prevention of any disease or condition covered by Intellect's patents. ViroPharma paid Intellect Neurosciences a $6.5 million up-front licensing fee and would pay additional milestones based upon defined events.

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.